Source study found

Story checked

Cancer trial drug may work differently than scientists believed, raising concerns for clinical research (opens in a new tab)

medicalxpress.com · 2026-10-06

Short answerEvidenceSource

Short answer

Mostly not supported

Mostly not supported.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

1 supported
4 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail

The story

Cancer trial drug may work differently than scientists believed, raising concerns for clinical research

medicalxpress.com · 2026-10-06

The story’s checkable claims.

Read the original story

NewsLink checks it

Mostly not supported

The one claim we could check holds up. One of five claims matches the study. This overall rating is based only on the claims we could check. Four claims the study doesn't address.

1 supported
4 not covered

Open claim evidence

The source study

DHODH is the key target of the KDM4 inhibitor QC6352 in glioblastoma stem cells

Nature Chemical Biology · 2026

Open source record

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

Reading mode

Scan verdicts. Open evidence only when needed.

Browse by verdict

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5Not coveredA new study led by the University of Sydney says the experimental cancer drug zavondemstat and the related research compound QC6352 may have entered clinical trials on the basis of an incorrect understanding of how they work.View evidenceHide evidence

Why this verdict

The abstract-level profile supports the narrower mechanistic point that QC6352 and zavondemstat's antiglioblastoma antiproliferative effects are independent of KDM4 inhibition and driven mainly by DHODH inhibition. However, the stronger lead framing that zavondemstat may have entered clinical trials on the basis of an incorrect understanding is not established in the supplied abstract profile; clinical-trial rationale and development history are not available at this evidence depth. The headline/lead implication therefore outruns what can be verified from the abstract.

Study evidence

QC6352 and its clinical analog zavondemstat produce antiproliferative activity in glioblastoma stem‑cell models.

“Using comprehensive chemical biology approaches in glioblastoma models, we demonstrate that the efficacy of QC6352 and that of its clinical analog zavondemstat are independent of KDM4 inhibition.”

Study evidence

DHODH is identified as the functional target driving the antiproliferative activity of QC6352 and zavondemstat in glioblastoma models.

“Instead, we identify dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine biosynthesis, as the functional target driving their antiproliferative activity.”

Claim 2 of 5Not coveredThe researchers say the finding could affect interpretation of previous studies using QC6352 and may have implications for the ongoing clinical development of zavondemstat.View evidenceHide evidence

Why this verdict

The abstract-level profile supports the idea that prior QC6352-based cellular mechanism interpretations may need caution, because QC6352 is described as a widely used KDM4 probe and the paper emphasizes orthogonal probes for mechanism-of-action assignment. But the supplied profile does not verify specific implications for ongoing clinical development of zavondemstat beyond identifying it as a clinical analog. The story's hedging helps, but the clinical-development component is not verifiable from the abstract profile.

Study evidence

DHODH is identified as the functional target driving the antiproliferative activity of QC6352 and zavondemstat in glioblastoma models.

“Instead, we identify dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine biosynthesis, as the functional target driving their antiproliferative activity.”

Study evidence

The orthogonal KDM4 inhibitor ML324, which lacks DHODH inhibition, fails to phenocopy QC6352 in glioblastoma cellular assays; this supports that QC6352/zavondemstat's antiproliferative efficacy is driven primarily by DHODH inhibition.

“the orthogonal KDM4 inhibitor ML324, which lacks DHODH inhibition, fails to phenocopy QC6352.”

Claim 3 of 5Not coveredThe discovery came from research investigating whether zavondemstat and QC6352 could be repurposed for glioblastoma, using patient-derived glioblastoma stem cells, tumor models, and genetic, mechanistic, and molecular experiments.View evidenceHide evidence

Why this verdict

The profile supports that the work was glioblastoma-focused and used glioblastoma stem-cell/cellular models with mechanistic chemical-biology and genetic/metabolic rescue experiments. However, the supplied abstract profile does not verify several specifics in the story claim, including a repurposing rationale, patient-derived status, and the nature of 'tumor models' beyond in vitro glioblastoma models. At abstract depth those details cannot be confirmed.

Study evidence

QC6352 and its clinical analog zavondemstat produce antiproliferative activity in glioblastoma stem‑cell models.

“Using comprehensive chemical biology approaches in glioblastoma models, we demonstrate that the efficacy of QC6352 and that of its clinical analog zavondemstat are independent of KDM4 inhibition.”

Study evidence

DHODH is identified as the functional target driving the antiproliferative activity of QC6352 and zavondemstat in glioblastoma models.

“Instead, we identify dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine biosynthesis, as the functional target driving their antiproliferative activity.”

Claim 4 of 5Not coveredThe article says the researchers also developed new compounds that inhibit KDM4 without affecting DHODH.View evidenceHide evidence

Why this verdict

The supplied profile reports use of an orthogonal KDM4 inhibitor, ML324, that lacks DHODH inhibition and fails to phenocopy QC6352. It does not state that the researchers developed new compounds that inhibit KDM4 without affecting DHODH. That development claim may require full-text evidence, but it is not verifiable from the abstract-level profile provided.

Study evidence

“the orthogonal KDM4 inhibitor ML324, which lacks DHODH inhibition, fails to phenocopy QC6352.”

Claim 5 of 5SupportedThe study, published in Nature Chemical Biology, found that zavondemstat and QC6352 do not primarily target KDM4; instead, both compounds largely work by blocking DHODH.View evidenceHide evidence

Why this verdict

The paper profile says the efficacy of QC6352 and clinical analog zavondemstat is independent of KDM4 inhibition in glioblastoma models, identifies DHODH as the functional target driving antiproliferative activity, and describes DHODH inhibition as the dominant driver. This supports the story's main mechanism claim, provided 'do not primarily target KDM4' is understood as a functional cellular mechanism claim rather than as saying the compounds have no KDM4 inhibitory activity at all; the profile actually characterizes them as dual KDM4-DHODH inhibitors.

Study evidence

QC6352 and its clinical analog zavondemstat produce antiproliferative activity in glioblastoma stem‑cell models.

“Using comprehensive chemical biology approaches in glioblastoma models, we demonstrate that the efficacy of QC6352 and that of its clinical analog zavondemstat are independent of KDM4 inhibition.”

Study evidence

DHODH is identified as the functional target driving the antiproliferative activity of QC6352 and zavondemstat in glioblastoma models.

“Instead, we identify dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine biosynthesis, as the functional target driving their antiproliferative activity.”

Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

Functional rescue evidence: uridine supplementation and expression of an inhibitor-resistant DHODH mutant reportedly fully abrogate growth inhibition.
This is important support for the DHODH mechanism. The story mentions genetic, mechanistic, and molecular experiments only generally and does not describe the specific metabolic and genetic rescue evidence summarized in the abstract profile.
From in_vitro cell-based rescue assays
Orthogonal-probe evidence: ML324, a KDM4 inhibitor lacking DHODH inhibition, fails to phenocopy QC6352, supporting DHODH-dominant mechanism and the need for orthogonal probes.
The story does not clearly report the ML324 phenocopy comparison. Claim c5 instead says researchers developed new compounds without DHODH activity, which is not the same as the abstract-profile evidence about ML324.
From orthogonal probe phenocopy comparison

2 things the story did carry across

Central mechanistic conclusion: QC6352 and zavondemstat show antiglioblastoma antiproliferative activity that is independent of KDM4 inhibition and driven predominantly by DHODH inhibition.
The paper characterizes QC6352 and zavondemstat as dual KDM4-DHODH inhibitors, with DHODH inhibition as the dominant driver of observed antiglioblastoma efficacy.

Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

Evidence read

study summary

Lead result

in vitro

1Lead resultin vitroIdentify DHODH as the functional target that drives the antiproliferative activity of QC6352/zavondemstat in glioblastoma models and establish functional rescue evidence (uridine; inhibitor-resistant DHODH mutant).in vitro chemical biology target identification/validationExpand

In plain English

Using chemical biology approaches in glioblastoma models, the paper reports that dihydroorotate dehydrogenase (DHODH) — rather than KDM4 — is the functional cellular target responsible for the antiproliferative activity of QC6352 and its clinical analog zavondemstat. Functional rescue by uridine and by expression of an inhibitor‑resistant DHODH mutant abolished growth inhibition, while an orthogonal KDM4 inhibitor (ML324) that does not inhibit DHODH failed to phenocopy QC6352. The authors conclude QC6352 and zavondemstat are dual KDM4–DHODH inhibitors and that DHODH inhibition is the dominant driver of their antiglioblastoma activity.

Key findings

DHODH is identified as the functional target driving the antiproliferative activity of QC6352 and zavondemstat in glioblastoma models.
Uridine supplementation fully abrogates growth inhibition by QC6352/zavondemstat, supporting on-target DHODH inhibition.

“Instead, we identify dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine biosynthesis, as the functional target driving their antiproliferative activity.”

What this piece can’t prove

4 further details could not be confirmed from the summary.

2in vitroDetermine whether QC6352 (and its clinical analog zavondemstat) exerts antiglioblastoma effects through on-target KDM4 inhibition or via an alternative functional target.in vitro cell‑based chemical biology (GSC antiproliferative and rescue experiments)Expand

In plain English

In glioblastoma stem-cell models, the KDM4 chemical probe QC6352 and its clinical analog zavondemstat show antiproliferative activity that the authors attribute to inhibition of dihydroorotate dehydrogenase (DHODH) rather than on-target KDM4 inhibition. Uridine supplementation and expression of an inhibitor‑resistant DHODH mutant reportedly fully abrogate the growth inhibition, while an orthogonal KDM4 inhibitor (ML324), which lacks DHODH activity, does not phenocopy QC6352. The authors conclude QC6352 and zavondemstat act as dual KDM4–DHODH inhibitors with DHODH inhibition the dominant driver of antiglioblastoma efficacy.

Key findings

QC6352 and its clinical analog zavondemstat produce antiproliferative activity in glioblastoma stem‑cell models.
The antiproliferative efficacy of QC6352/zavondemstat is independent of KDM4 inhibition.

“Using comprehensive chemical biology approaches in glioblastoma models, we demonstrate that the efficacy of QC6352 and that of its clinical analog zavondemstat are independent of KDM4 inhibition.”

What this piece can’t prove

Summary is based solely on the paper abstract provided; full experimental details, data, and supporting figures are not available in the supplied text.
Inference about mechanism relies on author's reported rescue and comparator experiments; the abstract does not present raw data or methodological specifics needed to assess robustness or reproducibility.

2 further details could not be confirmed from the summary.

3in vitroIdentify DHODH as the functional target that drives the antiproliferative activity of QC6352/zavondemstat in glioblastoma models and establish functional rescue evidence (uridine; inhibitor-resistant DHODH mutant).in vitro cell-based rescue assaysExpand

In plain English

Abstract reports two independent functional rescue experiments — metabolic (uridine supplementation) and genetic (expression of an inhibitor-resistant DHODH mutant) — that fully abrogate QC6352/zavondemstat-mediated growth inhibition in glioblastoma models, supporting DHODH as the functional target driving the compounds' antiproliferative activity.

Key findings

Two independent rescue modalities — uridine supplementation and expression of an inhibitor-resistant DHODH mutant — fully abrogate QC6352/zavondemstat-mediated growth inhibition in glioblastoma models, implicating DHODH as the functional target driving antiproliferative activity.

“Uridine supplementation and expression of an inhibitor-resistant DHODH mutant fully abrogate growth inhibition”

What this piece can’t prove

Summary is based solely on the abstract; experimental methods and full data (cell lines, concentrations, timepoints, replicates, statistical analyses) are not provided here.
Abstract does not provide mechanistic readouts (e.g., pyrimidine nucleotide measurements) that would further substantiate the biochemical link between DHODH inhibition and growth phenotype.

2 further details could not be confirmed from the summary.

4in vitroDemonstrate lack of phenocopy by an orthogonal KDM4 inhibitor (ML324) that lacks DHODH inhibition, supporting DHODH-dominant mechanism and the need for orthogonal probes in cellular MOA assignment.orthogonal probe phenocopy comparisonExpand

In plain English

In glioblastoma cellular models (including glioblastoma stem cells), the orthogonal KDM4 inhibitor ML324 — reported to lack DHODH inhibition — did not reproduce (phenocopy) the antiproliferative effect of QC6352. This observation, reported alongside evidence that QC6352 and its clinical analog zavondemstat inhibit DHODH and that DHODH perturbation (uridine rescue and inhibitor-resistant DHODH) abrogates growth inhibition, supports the interpretation that DHODH inhibition is the dominant driver of QC6352's antiglioblastoma cellular efficacy and illustrates the need for orthogonal chemical probes in assigning cellular mechanism of action.

Key findings

The orthogonal KDM4 inhibitor ML324, which lacks DHODH inhibition, fails to phenocopy QC6352 in glioblastoma cellular assays; this supports that QC6352/zavondemstat's antiproliferative efficacy is driven primarily by DHODH inhibition.